All In Biotech

Drug Trial Radar · NCT00634660

Safety and Tolerability Study of rAvPAL-PEG to Treat Phenylketonuria

A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single, Subcutaneous Doses of rAvPAL-PEG in Subjects With Phenylketonuria

Last checked: Nov 20, 2026Latest source record: Feb 1, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

25

Actual

Start

May 2008

Primary completion

Apr 2009

Study completion Oct 2009

Sponsor

Lead sponsor
BioMarin PharmaceuticalBioMarin (BMRN)
Sponsor type
Industry
First posted
Mar 13, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and tolerability of injections of rAvPAL-PEG in subjects with PKU.

Conditions

  • Phenylketonuria

Interventions

  • rAvPAL-PEGDrug

    rAvPAL-PEG will be administered as a single, SC injection at dose levels of 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, and 1.0 mg/kg. The duration of treatment is a single dose of study drug with 42 days (6 weeks) of follow-up.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. • To assess the incidence of treatment-emergent adverse events of a single, subcutaneous (SC) injections of rAvPAL-PEG in subjects with PKU.Time frame: 6 weeks

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Children's Memorial Hospital

    Chicago, Illinois

  • University of Minnesota Medical Center-Fairview

    Minneapolis, Minnesota

  • Washington University Center for Applied Research Sciences

    St Louis, Missouri

  • Mount Sinai Medical Center

    New York, New York

  • Oregon Health & Science University

    Portland, Oregon

  • University of Pittsburgh

    Pittsburgh, Pennsylvania

  • University of Utah Hospital

    Salt Lake City, Utah

  • University of Wisconsin

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.